{"url_path":"/sec/mlys/8-k/2026-08-11/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1933414/0001933414-26-000112-index.html","accession_number":"0001933414-26-000112","cik":"0001933414","ticker":"MLYS","issuer_name":"Mineralys Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1933414/0001933414-26-000112-index.html","primary_entity_key":"0001933414","primary_entity_name":"Mineralys Therapeutics, Inc."},"word_count":146,"has_tables":true,"body_markdown":"Item 2.02 Results of Operations and Financial Condition.\n\nOn August 11, 2026, Mineralys Therapeutics, Inc. (the Company) issued a press release announcing its financial results for the quarter ended June 30, 2026 and provided a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.\n\nIn accordance with General Instruction B.2 of Form 8-K, the information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing."}